


## TOTAL SYNTHESIS OF LEUKOTRIENE (+)-LTB<sub>4</sub> FROM D-MANNITOL<sup>1</sup>

Y. Le Merrer, C. Gravier, D. Languin-Micas and J.C. Depezay\*

Université René Descartes, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques (Unité Associée au CNRS n° 400)  
45 rue des Saints Pères, 75270 PARIS Cedex 06, FRANCE.

**Abstract :** A total convergent synthesis of leukotriene (+)-LTB<sub>4</sub> has been carried out via two enantiomerically pure  $\alpha$ -hydroxyaldehydes, chiral key intermediates both obtained from D-mannitol and connected at a four carbon atoms interval by Wittig reactions.


We have previously reported<sup>2</sup> a general method to prepare enantiomerically pure  $\alpha$ -hydroxyaldehydes of R or S configuration from D-mannitol. These aldehydes are chiral key intermediates for the synthesis of arachidonic acid metabolites. The strategy is based on nucleophilic opening of diastereoisomeric diepoxides 1 and 2. We have now used this approach for a total convergent synthesis of (+)-LTB<sub>4</sub><sup>3</sup>:




The first part of our work is concerned with the preparation of suitably protected ( $Z = t\text{BDPSi}$ ,  $Z' = \text{C}_6\text{H}_5\text{CO}$ ) enantiomerically pure aldehydes A (R) and B (S). Two moles of each are obtained from one mole of D-mannitol without "wastage of carbons".

Suitably protected  $\alpha$ -hydroxyaldehyde A results (Scheme I) from nucleophilic opening of the diepoxide<sup>2</sup> 1 (1,2 : 5,6-dianhydro-3,4-O-methylethylidene-D-mannitol) by lithium heptynide followed by silylation *in situ*, controlled hydrogenation of the triple bonds (1  $\rightarrow$  3), removal of the acetonide group (3  $\rightarrow$  4) and oxidative cleavage of the 3,4-diol (4  $\rightarrow$  A).


In the presence of bulky tert-butyldiphenylsilyl (tBDPSi) protecting groups, hydrolysis of the acetonide using aqueous trifluoroacetic acid is not complete at 0°C and silicium-oxygen bond cleavage occurs at higher temperatures. Indeed deprotection of the glycol by trans-thioketalisation<sup>4</sup> affords crude diol 4. Aldehyde A (R) is obtained with 33 % overall yield

Scheme I - Synthesis of aldehyde A(R)<sup>10</sup>

a : ref. 1 - b : 2,2eq.  $C_5H_4-C\equiv C-Li$ , THF, HMPT, 65°C, 2h30 then tBOPSiCl, 65°C, 16h30 ; 60 % - c : Lindlar cat.,  $H_2$ ,  $C_6H_6$ ; 100 % - d : 7eq.  $(CH_2SH)_2$ , 0,2eq. TSOH,  $CHCl_3$ , 60°C, 3h - e: 1,1eq.  $Pb(OAc)_4$ ,  $C_6H_6$ , RT, 1h ; d + e : 55 %

Scheme II - Synthesis of aldehyde B(S)<sup>10</sup>

a : ref. 1 - b : 6eq.  $LiC\equiv C-CO_2Et$ , 6eq.  $BF_3-OEt_2$ , THF, - 78°C, 2h then  $NH_4Cl$  aq.Sat. - c : 2,5eq.  $PhCOCl$ , pyr, 20°C, 2h ; b + c : 80 % - d :  $H_2$ , Pt,  $C_2H_5OH$  ; 100 % - e : TFA,  $H_2O$  9/1, -5°C, 3h30 ; 90 % - f : 1,1eq.  $Pb(OAc)_4$ ,  $CH_2Cl_2$ , - 10°C, 1h ; 65 %

Scheme III - Synthesis of conjugated triene-LTB<sub>4</sub> + Δ<sup>6,7</sup> trans isomer<sup>10</sup>

a : 1,2eq.  $Ph_3P=CH-CHO$ ,  $C_6H_6$ , 80°C, 6h ; 60 % - b : 1,2eq.  $(EtO)_2POCH_2CO_2Et$ , 1eq. DBU, 1,2eq. LiCl,  $CH_3CN$ , RT, 1h ; 65 %  
c : 1,3eq.  $AlH_3$ , THF, 0°C, 2h30 - d : 3,3eq.  $CBr_4$ , 1,5eq. DIPHOS,  $CH_2Cl_2$ , - 35°C, 2h30 - e : 1,2eq.  $Ph_3P$ ,  $CH_3CN$ , RT, 2h30 ; c + d + e : 75 % - f : 1eq. BuLi, THF, - 100°C, 2mn then 1,5eq. HMPT, - 100°C → RT ; 80 % - g : 10eq.  $nBu_4NF$ , THF - h : 10eq.  $K_2CO_3$ , MeOH-H<sub>2</sub>O 4/1.

from diepoxyde 1.

The synthesis of the protected aldehyde B (S) (Scheme II) begins with the nucleophilic opening of the diepoxyde 2 (1,2 : 5,6-dianhydro-3,4-O-methylethyldene-L-iditol) by lithio ethylpropionate (large excess) in the presence of boron trifluoride-etherate at -78 °C<sup>5</sup>. The diol is then benzyolated and triple bonds are reduced (2→5). Hydrolysis of the acetonide 5 and cleavage of the 3,4-diol 6 leads to aldehyde B (S) in 47 % of overall yield from diepoxyde 2.

In the second part of the synthesis (Scheme III), a four carbon atom junction between the two aldehydes A and B is realized by successive Wittig condensations according to a scheme previously described<sup>3d</sup>. We have modified some experimental conditions. In particular during the Horner-Wadsworth-Emmons reaction (7→8) we used conditions<sup>6</sup> more appropriate for base sensitive aldehydes. For the transformation of allylic alcohol 9 into bromide 10 use of DIPHOS<sup>7</sup> ( $\text{Ph}_2\text{CH}_2$ )<sub>2</sub> instead of triphenylphosphine facilitates purification since "diphos monoxyde" is more easily separated than triphenylphosphine oxide.

The last Wittig reaction leads to a mixture of the two diastereoisomers  $\Delta^{6,7}$  cis and  $\Delta^{6,7}$  trans (double bond isomers ; ratio 12 : 13, ca. 7 : 3). These compounds are easily separated by HPLC<sup>8</sup> and fully characterised. Each isomer has been sequentially deprotected and the potassium salt of (+)-LTB<sub>4</sub> obtained is identical (HPLC, UV)<sup>9</sup> with a sample supplied by J. Rokach.

The study of LTB<sub>4</sub> metabolism by different systems (P.M.N.L. and hepatic microsomes of rat) shows that the metabolic profile obtained is superposable to the one obtained from Rokach's sample of LTB<sub>4</sub>.

Starting from an inexpensive chiral natural compound, via diepoxydes, this synthesis of (+)-LTB<sub>4</sub> has been accomplished according to a flexible strategy which is easily applicable to synthesis of analogs or modified LTB<sub>4</sub> and of hydroxy eicosatetraenoic acids (HETE).

#### ACKNOWLEDGEMENTS

We express our thanks to Dr. Marcel Delaforge, J. Leclaire and Dr. J.P. Girault of our department, respectively for their biological studies, LTB<sub>4</sub> comparisons and for NMR (250 MHz) studies. Financial aid of this work was provided by C.N.R.S. in the section PIRMED-ASP "Lipides pharmacologiquement actifs".

#### REFERENCES AND NOTES

- Presented in "Société Française de Chimie", organic division meeting, Paris March 1986, oral communication ; "1st Belgian Organic Synthesis Symposium", Belgian Chemical Society, Namur May 1986, poster.
- Y. Le Merrer, A. Dureault, C. Gravier, D. Languin, J.C. Depezay, Tetrahedron Lett., 1985, 26, 319.
- a) E.J. Corey, A. Marfat, G. Goto, F. Brion, J. Am. Chem. Soc., 1980, 102, 7984.  
b) E.J. Corey, A. Marfat, J. Munroe, K.S. Kim, P.B. Hopkins, F. Brion, Tetrahedron Lett., 1981, 22, 1077.
- c) Y. Guindon, R. Zamboni, C.K. Lau, J. Rokach, Tetrahedron Lett., 1982, 23, 739.
- d) R. Zamboni, J. Rokach, Tetrahedron Lett. 1982, 23, 2631.
- e) K.C. Nicolaou, R.E. Zipkin, R.E. Dolle, B.D. Harris, J. Am. Chem. Soc., 1984, 106, 3548.

- f) J. Rokach, J. Adams. *Acc. Chem. Res.*, 1985, **18**, 87.  
g) Chao-Qi Han, D. Di Tullio, Yi-Fong Wang, C.J. Sih, *J. Org. Chem.*, 1986, **51**, 1253.  
4. D.R. Williams, Sing-Yuen Sit, *J. Am. Chem. Soc.*, 1984, **106**, 2949.  
5. M.J. Eis, J.E. Wrobel, B. Ganem, *J. Am. Chem. Soc.*, 1984, **106**, 3693.  
6. S. Masamune, W.R. Roush, *Tetrahedron Lett.*, 1984, **25**, 2183.  
7. J. Rokach, J. Adams, R. Perry, *Tetrahedron Lett.*, 1983, **24**, 5185.  
8. Waters μ-Porasil column ; 98.5 % hexane / .5 % AcOEt / 1 % Et<sub>3</sub>N as solvent, retention volumes : **12**, 11.60 ; **13**, 13.60.  
9. HPLC : solvent gradient system (CH<sub>3</sub>CN / H<sub>2</sub>O with .1 % AcOH) on a Spherisorb ODS 2 5 μcolumn . UV : 261, 269, 281 nm.  
10. All new compounds exhibited satisfactory spectra and analytical data.
- A (R) : Ebo.05 ~ 168°C (Buchi) - [α]<sub>D</sub><sup>20</sup> = -14.5° (c 2.2, CHCl<sub>3</sub>) [Litt : -16.5° (c 3.0, CHCl<sub>3</sub>)<sup>39</sup>; -18° (c 2, CHCl<sub>3</sub>)<sup>2d</sup>] - <sup>1</sup>H NMR (90 MHz, CDCl<sub>3</sub>) : 0.85 (t, 3H), 1.10 (s, 9H), 1.25, (m, 6H), 1.9 (m, 2H), 2.4 (m, 2H), 4.1 (dt, 1H, 6Hz, 1.8Hz), 5.4 (m, 2H), 7.4-7.7 (2m, 10H), 9.5 (d, 1H, 1.8 Hz) - <sup>13</sup>C NMR (CDCl<sub>3</sub>) : 202.2 (d), 135.4 (d), 133.0 (d), 132.8 (s), 132.6 (s), 129.6 (d), 127.4 (d), 122.3 (d), 77.7 (d), 37.3 (t), 31.5 (t), 29.1 (t), 27.3 (t), 27.0 (q), 22.6 (t), 19.4 (s), 14.1 (q). SM (NH<sub>3</sub>) : 426 (M<sup>+</sup>+18).
- B (S) : Ebo.02 ~ 100°C (Buchi) - [α]<sub>D</sub><sup>25</sup> = -39° (c 0.5, CHCl<sub>3</sub>) [Litt : -46° (c 0.5, CHCl<sub>3</sub>)<sup>3c</sup>; enantiomer : +35° (c 2, CHCl<sub>3</sub>)<sup>3d</sup>] - <sup>1</sup>H NMR (90 MHz, CDCl<sub>3</sub>) : 1.25 (t, 3H, 7.5Hz); 1.95 (m, 4H), 2.40 (t, 2H, 7.25Hz), 4.15 (q, 2H), 5.30 (t, 1H, 7Hz), 7.60-8.15 (2m, 5H), 9.75 (s, 1H) - <sup>13</sup>C NMR (CDCl<sub>3</sub>) : 197.8 (d), 172.6 (s), 165.9 (s), 133.5 (d), 129.8 (d), 129.1 (s), 128.5 (d), 78.3 (d), 60.4 (t), 33.6 (t), 28.3 (t), 20.5(t), 14.1 (q).
- 7 [α]<sub>D</sub><sup>20</sup> = -13° (c 1.55, CHCl<sub>3</sub>) [Litt<sup>39</sup> : -14.4° (c 2.0, CHCl<sub>3</sub>)].
- 8 [α]<sub>D</sub><sup>20</sup> = 43° (c 2.2, CHCl<sub>3</sub>) [Litt : 40.6° (c 2.0, CHCl<sub>3</sub>)<sup>39</sup>, 45° (c 3.0, CHCl<sub>3</sub>)<sup>3d</sup>].
- 72 <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 250 MHz) : 0.80 (t, 3H), 0.90 (t, 3H), 1.10-1.40 (m, 15H), 1.60 (m, 4H), 1.85 (m, 2H), 2.10 (m, 2H), 2.35 (m, 2H), 3.80 (q, 2H), 4.30 (m, 1H, H<sub>12</sub>), 5.30 (dd, 1H, H<sub>6</sub>), 5.45 (ddd, 1H, H<sub>15</sub>), 5.47 (ddd, 1H, H<sub>14</sub>), 5.70 (dd, 1H, H<sub>11</sub>), 5.95 (dd, 1H, H<sub>10</sub>), 6.0 (dd, 1H, H<sub>7</sub>), 6.05 (m, 1H, H<sub>9</sub>), 6.10 (ddd, 1H, H<sub>5</sub>), 6.70 (dd, 1H, H<sub>8</sub>), 7.0-8.10 (2m, 5H), 7.20-7.80 (2m, 10H), J<sub>4,5</sub> = 5.5, J<sub>5,6</sub> = 9.5, J<sub>6,7</sub> = 10.5, J<sub>7,8</sub> = 11.5, J<sub>8,9</sub> = 14, J<sub>9,10</sub> = 10.2, J<sub>10,11</sub> = 14.5, J<sub>11,12</sub> = 7.2, J<sub>14,15</sub> = 11Hz - <sup>13</sup>C NMR (C<sub>6</sub>D<sub>6</sub>) : 172.3 (C<sub>1</sub>) ; 165.6 (BzCO) ; 137.6, 136.4, 135.3, 132.6, 132.3, 130.9, 130.7, 129.9, 128.9, 128.4, 128.2 125.0 (Ph, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>14</sub>, C<sub>15</sub>) ; 74.7 (C<sub>12</sub>) ; 70.7 (C<sub>5</sub>) ; 60.0 (CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) ; 36.6, 34.7, 34.0, 31.8, 29.6, 27.8, 22.9, 20.9, (C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>13</sub>, C<sub>16</sub>, C<sub>17</sub>, C<sub>18</sub>, C<sub>19</sub>) ; 27.3, 19.6 (tBu) ; 14.1 (CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C<sub>20</sub>) - SM (NH<sub>3</sub>) : 724 (M<sup>+</sup>+18) - UV (C<sub>2</sub>H<sub>5</sub>OH) : 263, 272, 283 nm.
- 13 <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 400MHz) : 0.80 (t, 3H), 0.90 (t, 3H), 1.10-1.40 (m, 15H), 1.60 (m, 4H), 1.85 (m, 2H), 2.05 (t, 2H), 2.40 (m, 2H), 3.90 (q, 2H), 4.40 (ddd, 1H, H<sub>12</sub>), 5.45 (m, 2H, H<sub>14</sub>, H<sub>15</sub>), 5.50 (ddd, 1H, H<sub>6</sub>), 5.70 (dd, 1H, H<sub>11</sub>), 5.95 (m, 1H, H<sub>8</sub>), 6.0 (m, 1H, H<sub>9</sub>), 6.10 (dd, 1H, H<sub>10</sub>), 6.30 (ddd, 1H, H<sub>7</sub>), 7.05-8.20 (2m, 5H), 7.20-7.80 (2m, 10H), J<sub>4,5</sub> = 5.5, J<sub>5,6</sub> = 7.5, J<sub>6,7</sub> = 14, J<sub>6,8</sub> = 2, J<sub>7,8</sub> = 9.5, J<sub>7,9</sub> = 2.5, J<sub>9,10</sub> = 9, J<sub>10,11</sub> = 15, J<sub>11,12</sub> = 7, J<sub>12,13</sub> = 5.5, J<sub>14,15</sub> = 11Hz - <sup>13</sup>C NMR (C<sub>6</sub>D<sub>6</sub>) : 172.3 (C<sub>1</sub>) ; 165.3 (BzCO) ; 137.0, 136.3, 133.8, 133.2, 132.8, 132.4, 131.8, 131.2, 130.4, 129.9, 124.9 (Ph, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>14</sub>, C<sub>15</sub>) ; 74.6 (C<sub>12</sub>) ; 74.4 (C<sub>5</sub>) ; 60.0 (CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) ; 36.6, 34.2, 33.9, 31.8, 29.6, 27.8, 23.0, 21.0 (C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>13</sub>, C<sub>16</sub>, C<sub>17</sub>, C<sub>18</sub>, C<sub>19</sub>) ; 27.3, 19.6 (tBu) ; 14.3 (CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C<sub>20</sub>) - SM (NH<sub>3</sub>) : 724 (M<sup>+</sup>+18) - UV (C<sub>2</sub>H<sub>5</sub>OH) : 262, 270, 282 nm.

(Received in France 2 June 1986)